A few years ago, I reviewed a blood test called VeriStrat that evaluates the patterns of proteins in the blood and reports a profile of either “Good” (in about 2/3 of patients with advanced NSCLC) or “Poor” (in the remaining 1/3 of patients) for EGFR inhibitor therapy.

An interesting article just came out in the Journal of Clinical Oncology from researchers at Duke, led by Dr. Ed Patz of the Radiology Department there (abstract here).